🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. BLB-750 Vaccine (Qinghai RG strain)

    Takeda

    Pandemic Influenza Prevention

    approved mab completed

    1 trial

  2. Brentuximab vedotin

    Takeda

    Lymphoma

    approved small molecule active

    2 trials

  3. Brentuximab vedotin

    Takeda

    T-Cell Lymphoma

    approved small molecule completed

    1 trial

  4. C1 inhibitor (human) [C1 INH]

    Takeda

    Hereditary Angioedema

    approved mab completed

    1 trial

  5. CDPATH™

    Takeda

    Crohn's Disease

    approved other active

    1 trial

  6. Caffeine

    Takeda

    Colitis, Ulcerative

    approved small molecule terminated

    1 trial

  7. Calcichew D3

    Takeda

    Calcium and Vitamin D Deficiencies

    approved small molecule completed

    1 trial

  8. Candesartan

    Takeda

    Cerebrovascular Accident

    approved small molecule active

    1 trial

  9. Candesartan and Hydrochlorothiazide

    Takeda

    Obesity

    approved small molecule completed

    1 trial

  10. Candesartan cilexetil and hydrochlorothiazide

    Takeda

    Hypertension

    approved small molecule completed

    1 trial

  11. Cardiovascular drugs strategies

    Takeda

    High Risk Hypertensive Patients

    approved other completed

    1 trial

  12. Ciclesonide

    Takeda

    Allergic Rhinitis

    approved small molecule completed

    1 trial

  13. Colchicine

    Takeda

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  14. Colchicine

    Takeda

    Pharmacokinetics

    approved small molecule completed

    1 trial

  15. Coumarin/troxerutin

    Takeda

    Chronic Venous Insufficiency

    approved small molecule completed

    1 trial

  16. Darvadstrocel

    Takeda

    Crohn's Disease

    approved mab terminated

    3 trials

  17. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux Disease

    approved small molecule completed

    4 trials

  18. Dexlansoprazole 60 MG

    Takeda

    GERD

    approved small molecule completed

    1 trial

  19. Digital Engagement Application (GD App)

    Takeda

    Gaucher Disease

    approved other completed

    1 trial

  20. Double dose of PPI

    Takeda

    Dyspepsia

    approved small molecule completed

    1 trial

  21. Dynepo

    Takeda

    Anemia

    approved small molecule terminated

    1 trial

  22. ELAPRASE

    Takeda

    Mucopolysaccharidosis (MPS)

    approved small molecule terminated

    1 trial

  23. Elaprase

    Takeda

    Hunter Syndrome

    approved mab completed

    1 trial

  24. Elaprase for intravenous (IV) infusion

    Takeda

    Hunter Syndrome

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources